Source: Stock image generated with AI.

Key Highlights

  • Marvel Biosciences awarded 59,693 deferred share units to three independent directors instead of cash fees.
  • The deferred share units vest on November 18, 2027 and are settled when a director leaves the company.
  • The units were valued using a $0.13 volume-weighted average share price on November 17, 2026.

Marvel Biosciences Corp. (TSXV: MRVL) has awarded 59,693 deferred share units to its three independent directors in place of cash payment for directors’ fees, according to a company press release.

The company said the deferred share units (DSUs) will all vest on November 18, 2027. Once vested, the DSUs are to be settled when a director separates from service from the company, and the DSUs expire 365 days after that separation.

This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.

Marvel said the deemed value of the DSUs was calculated using the volume-weighted average price of its common shares on the TSX Venture Exchange on November 17, 2026, which it reported as $0.13, multiplied by the number of DSUs awarded.

Marvel Biosciences, through its wholly owned subsidiary Marvel Biotechnology Inc., describes itself as a Calgary-based pre-clinical stage biotechnology company developing MB-204, a fluorinated derivative of the anti-Parkinson’s drug istradefylline.

Read the original press release on Stockhouse.com.

More From The Market Online

Plurilock shareholders approve Quantum eMotion acquisition plan

Plurilock shareholders backed Quantum eMotion's proposed takeover, with court approval sought Nov. 20, 2026 and C$0.28 per share implied.

Kaplan Fox says Nvidia faces securities class action

Kaplan Fox says a class action was filed against NVIDIA (NASDAQ: NVDA), with a proposed investor class period from Dec. 2024 to Nov. 2026.

@ the Bell: TSX sinks as Nvidia delivers strong earnings growth

Canada’s resource-heavy stock index sunk lower on Wednesday as declining oil and gold prices weighed on...

Microsoft and Intel expand Azure infrastructure agreement

Microsoft and Intel expanded a long-term deal to develop Azure cloud and AI infrastructure, including Intel EMIB packaging and multi-year Xeon supply.